{"id":22280,"date":"2024-03-01T09:38:44","date_gmt":"2024-03-01T08:38:44","guid":{"rendered":"http:\/\/mabdesign.fr\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/"},"modified":"2024-03-01T09:47:21","modified_gmt":"2024-03-01T08:47:21","slug":"maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/","title":{"rendered":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)"},"content":{"rendered":"\n<p>MaaT Pharma (EURONEXT: MAAT &#8211; the &#8220;Company&#8221;), a late-stage biotechnology company and leader in the development of Microbiome Ecosystem TherapiesTM (MET)[1] to improve survival in cancer patients, today announced that the DSMB has reviewed the safety data from the first 8 Amyotrophic Lateral Sclerosis (ALS) patients treated with MaaT033 in the IASO clinical trial. The DSMB has recommended that the trial continue unchanged. <a href=\"https:\/\/www.maatpharma.com\/fr\/29-fevrier-2024-maat-pharma-annonce-levaluation-positive-par-le-dsmb-de-lessai-de-phase-1-en-cours-evaluant-maat033-dans-la-sclerose-laterale-amyotrophique-sla\/\">To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)<\/p>\n","protected":false},"author":3,"featured_media":20983,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-22280","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) - MabDesign<\/title>\n<meta name=\"description\" content=\"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) - MabDesign\" \/>\n<meta property=\"og:description\" content=\"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-01T08:38:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-01T08:47:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"150\" \/>\n\t<meta property=\"og:image:height\" content=\"171\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Laure Delhon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laure Delhon\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/\"},\"author\":{\"name\":\"Laure Delhon\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\"},\"headline\":\"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)\",\"datePublished\":\"2024-03-01T08:38:44+00:00\",\"dateModified\":\"2024-03-01T08:47:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/\"},\"wordCount\":82,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/\",\"name\":\"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png\",\"datePublished\":\"2024-03-01T08:38:44+00:00\",\"dateModified\":\"2024-03-01T08:47:21+00:00\",\"description\":\"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\",\"name\":\"Laure Delhon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"caption\":\"Laure Delhon\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) - MabDesign","description":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/","og_locale":"en_US","og_type":"article","og_title":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) - MabDesign","og_description":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)","og_url":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/","og_site_name":"MabDesign","article_published_time":"2024-03-01T08:38:44+00:00","article_modified_time":"2024-03-01T08:47:21+00:00","og_image":[{"width":150,"height":171,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png","type":"image\/png"}],"author":"Laure Delhon","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Laure Delhon"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/"},"author":{"name":"Laure Delhon","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39"},"headline":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)","datePublished":"2024-03-01T08:38:44+00:00","dateModified":"2024-03-01T08:47:21+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/"},"wordCount":82,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/","url":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/","name":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png","datePublished":"2024-03-01T08:38:44+00:00","dateModified":"2024-03-01T08:47:21+00:00","description":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2016\/08\/maat-logo-rvb-header.png","width":150,"height":171},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/maat-pharma-announces-positive-evaluation-by-dsmb-of-phase-1-trial-in-progress-evaluating-maat033-in-amyotrophic-lateral-sclerosis-sla\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma announces positive DSMB review of ongoing Phase 1 trial evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39","name":"Laure Delhon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","caption":"Laure Delhon"},"url":"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=22280"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22280\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/20983"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=22280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=22280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=22280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}